When buying a private company, you can pay a lot in milestone payments (that is, pay only if the drug continues to be successful). It's much harder to do so with a publicly listed company... As generally you'll need to pay all the amount upfront...Which the bios prefer not to do. It's much easier to commit 550 odd million of a billion dollar payment AFTER the drug is proven commercial.
Even so, if we just got the cash upfront payment of Biovex (420 odd US million) we're laughing...
So hopefully we'll see some movement at the station soon.
- Forums
- ASX - By Stock
- VLA
- Roth Report
Roth Report, page-40
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some